Literature DB >> 16075796

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!

Rachel Midgley1, David J Kerr.   

Abstract

Colorectal cancer is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and improved surgery. Adjuvant chemotherapy is now considered the standard treatment for stage III colon cancer, and has evolved recently with the introduction of infusional, combination chemotherapy. Adjuvant therapy for stage II colon cancer has been more controversial. Recent trial data suggest, however, that there is a legitimate case for discussing the advantages and limitations with individual patients.

Entities:  

Mesh:

Year:  2005        PMID: 16075796     DOI: 10.1038/ncponc0228

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  16 in total

1.  The Arf/p53 protein module, which induces apoptosis, down-regulates histone H2AX to allow normal cells to survive in the presence of anti-cancer drugs.

Authors:  Yuko Atsumi; Aki Inase; Tomoyuki Osawa; Eiji Sugihara; Ryo Sakasai; Hiroaki Fujimori; Hirobumi Teraoka; Hideyuki Saya; Masamoto Kanno; Fumio Tashiro; Hitoshi Nakagama; Mitsuko Masutani; Ken-ichi Yoshioka
Journal:  J Biol Chem       Date:  2013-03-27       Impact factor: 5.157

2.  Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome.

Authors:  Amanda G Hansen; Tanner J Freeman; Shanna A Arnold; Alina Starchenko; Celestial R Jones-Paris; Michael A Gilger; Mary K Washington; Kang-Hsien Fan; Yu Shyr; Robert D Beauchamp; Andries Zijlstra
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

Review 3.  Development and progression of colorectal neoplasia.

Authors:  Upender Manne; Chandrakumar Shanmugam; Venkat R Katkoori; Harvey L Bumpers; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.

Authors:  Hong-Hwa Chen; William Tzu-Liang Chen; Hsin-Chung Lee; Jen-Kou Lin; Chuan-Yin Fang; Yenn-Hwei Chou; Peng-Chan Lin; Bo-Wen Lin; Chi-Chou Huang; Chung-Hung Yeh; Hsi-Hsien Hsu; Hung-Chang Chen; Wen-Chien Ting; Ming-Chin Yang; Elise Chia-Hui Tan
Journal:  Qual Life Res       Date:  2014-08-07       Impact factor: 4.147

5.  Colon cancer treatment costs for Medicare and dually eligible beneficiaries.

Authors:  Zhehui Luo; Cathy J Bradley; Bassam A Dahman; Joseph C Gardiner
Journal:  Health Care Financ Rev       Date:  2010

Review 6.  African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review.

Authors:  Dominik D Alexander; John Waterbor; Timothy Hughes; Ellen Funkhouser; William Grizzle; Upender Manne
Journal:  Cancer Biomark       Date:  2007       Impact factor: 4.388

7.  Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.

Authors:  R Soong; N Shah; M Salto-Tellez; B C Tai; R A Soo; H C Han; S S Ng; W L Tan; N Zeps; D Joseph; R B Diasio; B Iacopetta
Journal:  Ann Oncol       Date:  2008-02-01       Impact factor: 32.976

8.  Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

Authors:  Ioannis Kostopoulos; Vasilios Karavasilis; Maria Karina; Mattheos Bobos; Nikolaos Xiros; George Pentheroudakis; Georgia Kafiri; Pavlos Papakostas; Eleni Vrettou; George Fountzilas
Journal:  BMC Cancer       Date:  2009-09-24       Impact factor: 4.430

Review 9.  Adjuvant therapy for completely resected stage II colon cancer.

Authors:  Alvaro Figueredo; Megan E Coombes; Som Mukherjee
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

10.  Cathepsin D Expression in Colorectal Cancer: From Proteomic Discovery through Validation Using Western Blotting, Immunohistochemistry, and Tissue Microarrays.

Authors:  Chandra Kirana; Hongjun Shi; Emma Laing; Kylie Hood; Rose Miller; Peter Bethwaite; John Keating; T William Jordan; Mark Hayes; Richard Stubbs
Journal:  Int J Proteomics       Date:  2012-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.